Integrating systemic and surgical approaches to treating metastatic colorectal cancer

Surgical Oncology Clinics of North America

Volumn 24, Issue 1, 2015, Pages 199-214

  Mi, Kaihong ^a   Kalady, Matthew F ^a,b   Quintini, Cristiano ^b   Khorana, Alok A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antiangiogenic therapy; Antineoplastic therapy; Colorectal cancer; Liver metastases; Liver directed therapy

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; REGORAFENIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ALOPECIA; ARTERIAL THROMBOEMBOLISM; ASYMPTOMATIC DISEASE; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; COLORECTAL SURGERY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; DRY SKIN; FATIGUE; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INFUSION RELATED REACTION; LIVER METASTASIS; LIVER RESECTION; LUNG TOXICITY; MAINTENANCE CHEMOTHERAPY; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; SYMPTOMATOLOGY; SYSTEMIC THERAPY; THROMBOCYTOPENIA; WOUND HEALING IMPAIRMENT; COLORECTAL NEOPLASMS; LIVER NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SECONDARY;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; PROGNOSIS;

EID: 84922953076     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2014.09.006     Document Type: Review

References (72)

1. Siegel R., Ma J., Zou Z., et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
2. Venook A.P., Niedzwiecki D., Lenz H.J., et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). JClin Oncol 2014, 32:5s.
3. Scheithauer W., Rosen H., Kornek G.V., et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993, 306(6880):752-755.
4. Goldberg R.M., Rothenberg M.L., Van Cutsem E., et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007, 12(1):38-50.
5. Grothey A., Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. JClin Oncol 2005, 23(36):9441-9442.
6. Colucci G., Gebbia V., Paoletti G., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. JClin Oncol 2005, 23(22):4866-4875.
7. Patt Y.Z., Lee F.C., Liebmann J.E., et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol 2007, 30(4):350-357.
8. Diaz-Rubio E., Tabernero J., Gomez-Espana A., et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the treatment of digestive tumors trial. JClin Oncol 2007, 25(27):4224-4230.
9. Porschen R., Arkenau H.T., Kubicka S., et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. JClin Oncol 2007, 25(27):4217-4223.
10. Sanoff H.K., Sargent D.J., Campbell M.E., et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. JClin Oncol 2008, 26(35):5721-5727.
11. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. JClin Oncol 2007, 25(13):1670-1676.
12. Masi G., Loupakis F., Pollina L., et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009, 249(3):420-425.
13. Bidard F.C., Tournigand C., Andre T., et al. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann Oncol 2009, 20(6):1042-1047.
14. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. JClin Oncol 2004, 22(2):229-237.
15. Rothenberg M.L., Oza A.M., Bigelow R.H., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. JClin Oncol 2003, 21(11):2059-2069.
16. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. JClin Oncol 2007, 25(12):1539-1544.
17. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. JClin Oncol 2005, 23(15):3502-3508.
18. Kabbinavar F.F., Hambleton J., Mass R.D., et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. JClin Oncol 2005, 23(16):3706-3712.
19. Vincenzi B., Santini D., Russo A., et al. Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. Cancer 2009, 115(20):4849-4856.
20. Hochster H.S., Hart L.L., Ramanathan R.K., et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. JClin Oncol 2008, 26(21):3523-3529.
21. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. JNatl Cancer Inst 2007, 99(16):1232-1239.
22. Bennouna J., Sastre J., Arnold D., et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013, 14(1):29-37.
23. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99(17):11393-11398.
24. Joulain F., Van Cutsem E., Iqbal S.U., et al. Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): mean overall survival (OS) estimation from a phase III trial (VELOUR). JClin Oncol 2012, 30(15). Abstract: 3602.
25. Allegra C.J., Lakomy R., Tabernero J., et al. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: a phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. JClin Oncol 2012, 30(15). Abstract: 3505.
26. Dahabreh I.J., Terasawa T., Castaldi P.J., et al. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011, 154(1):37-49.
27. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. JClin Oncol 2009, 27(12):2091-2096.
28. Douillard J.Y., Oliner K.S., Siena S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. NEngl J Med 2013, 369(11):1023-1034.
29. Loupakis F., Ruzzo A., Cremolini C., et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101(4):715-721.
30. Schwartzberg L.S., Rivera F., Karthaus M., et al. Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). JClin Oncol 2013, 31(15). Abstract: 3631.
31. Stintzing S, Jung A, Rossius L, etal. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Data presented at the 13th annual European Cancer Congress (ECC), Amsterdam, The Netherlands. September 28, 2013.
32. Van Cutsem E., Kohne C.H., Lang I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. JClin Oncol 2011, 29(15):2011-2019.
33. Sobrero A.F., Maurel J., Fehrenbacher L., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. JClin Oncol 2008, 26(14):2311-2319.
34. Andre T., Blons H., Mabro M., et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol 2013, 24(2):412-419.
35. Cohn A.L., Shumaker G.C., Khandelwal P., et al. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2011, 10(3):171-177.
36. Douillard J.Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. JClin Oncol 2010, 28(31):4697-4705.
37. Kohne C.H., Hofheinz R., Mineur L., et al. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. JCancer Res Clin Oncol 2012, 138(1):65-72.
38. Peeters M., Price T.J., Cervantes A., et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014, 25(1):107-116.
39. Seymour M.T., Brown S.R., Middleton G., et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013, 14(8):749-759.
40. Price T, Peeters M, Kim TW, etal. ASPECCT: a randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Data presented at the 2013 annual European Cancer Congress (ECC), Amsterdam, The Netherlands. September 29, 2013.
41. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. JClin Oncol 2007, 25(13):1658-1664.
42. Hecht J.R., Mitchell E., Chidiac T., et al. Arandomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. JClin Oncol 2009, 27(5):672-680.
43. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. NEngl J Med 2009, 360(6):563-572.
44. Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381(9863):303-312.
45. Chibaudel B., Maindrault-Goebel F., Lledo G., et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. JClin Oncol 2009, 27(34):5727-5733.
46. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. JClin Oncol 2006, 24(3):394-400.
47. Koopman M., Simkens L., May A., et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). JClin Oncol 2014, 32(3). Abstract: LBA388.
48. Ferrarotto R., Pathak P., Maru D., et al. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 2011, 10(3):178-182.
49. Rees M., Tekkis P.P., Welsh F.K., et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008, 247(1):125-135.
50. Fong Y., Fortner J., Sun R.L., et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230(3):309-318. [discussion: 318-21].
51. Tomlinson J.S., Jarnagin W.R., DeMatteo R.P., et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. JClin Oncol 2007, 25(29):4575-4580.
52. Pfannschmidt J., Dienemann H., Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007, 84(1):324-338.
53. Adam R., Wicherts D.A., de Haas R.J., et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. JClin Oncol 2009, 27(11):1829-1835.
54. Falcone A., Cremolini C., Masi G., et al. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): results of the phase III TRIBE trial by GONO group. JClin Oncol 2013, 31(15). Abstract: 3505.
55. Folprecht G., Gruenberger T., Bechstein W., et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 2014, 25(5):1018-1025.
56. Ye L.C., Liu T.S., Ren L., et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. JClin Oncol 2013, 31(16):1931-1938.
57. Wagman L.D., Geller D.A., Jacobs S.A., et al. NSABP FC-6: phase II study to determine surgical conversion rate in patients (pts) receiving neoadjuvant (NA) mFOLFOX7 plus dose-escalating cetuximab (C) for unresectable K-RAS wild-type (WT) colorectal cancer with metastases (mCRC) confined to the liver. Ann Surg Oncol 2014, 21:S13.
58. Goere D., Deshaies I., de Baere T., et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 2010, 251(4):686-691.
59. Kemeny N.E., Melendez F.D., Capanu M., et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. JClin Oncol 2009, 27(21):3465-3471.
60. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371(9617):1007-1016.
61. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013, 14(12):1208-1215.
62. Zhu D., Zhong Y., Wei Y., et al. Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases. PLoS One 2014, 9(1):e86543.
63. Adam R., Bismuth H., Castaing D., et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997, 225(1):51-60. [discussion: 60-2].
64. Kulik U., Bektas H., Klempnauer J., et al. Repeat liver resection for colorectal metastases. Br J Surg 2013, 100(7):926-932.
65. Jones R.P., Jackson R., Dunne D.F., et al. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg 2012, 99(4):477-486.
66. Verberne C.J., Wiggers T., Vermeulen K.M., et al. Detection of recurrences during follow-up after liver surgery for colorectal metastases: both carcinoembryonic antigen (CEA) and imaging are important. Ann Surg Oncol 2013, 20(2):457-463.
67. Fiorentini G., Aliberti C., Tilli M., et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012, 32(4):1387-1395.
68. Wong S.L., Mangu P.B., Choti M.A., et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. JClin Oncol 2010, 28(3):493-508.
69. McCahill L.E., Yothers G., Sharif S., et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. JClin Oncol 2012, 30(26):3223-3228.
70. de Mestier L., Manceau G., Neuzillet C., et al. Primary tumor resection in colorectal cancer with unresectable synchronous metastases: a review. World J Gastrointest Oncol 2014, 6(6):156-169.
71. Jegatheeswaran S., Mason J.M., Hancock H.C., et al. The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. JAMA Surg 2013, 148(4):385-391.
72. Sadanandam A., Lyssiotis C.A., Homicsko K., et al. Acolorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013, 19(5):619-625.